Skip to main
  1. Stocks
  2. Vertex Pharmaceuticals
  3. Forecast
VRTX

Vertex Pharmaceuticals (VRTX) Stock Forecast & Price Target

Vertex Pharmaceuticals (VRTX) Analyst Ratings

Based on 24 analyst ratings
Buy
Strong Buy 38%
Buy 50%
Hold 8%
Sell 4%
Strong Sell 0%

Bulls say

Vertex Pharmaceuticals is viewed favorably because its core cystic fibrosis franchise remains a durable, high-margin cash engine, with Q3 CF revenue of $3.27B and FY26 total revenue guidance raised to $13.15B-$13.25B on broad portfolio growth. Beyond CF, the company is increasingly diversified by the launch of Alyftrek, the expanding uptake of Journavx and Casgevy, and the pending Nov. 30 PDUFA for povetacicept, which could add another major growth leg if approved. Its pipeline breadth in kidney disease, pain, and diabetes, together with patent-protected CF leadership and multiple pivotal catalysts, supports expectations for sustained long-term revenue and earnings growth.

Bears say

Vertex Pharmaceuticals is exposed to meaningful downside as negative Pove data in IgAN could ripple across subsequent indications and undermine confidence in its renal franchise, which also faces setbacks or delays. Commercially, lower-than-expected uptake of Alyftrek and Journavx, alongside pricing pressure in cystic fibrosis and acute pain, could slow diversification away from the CF core. Competition and potential safety issues for pipeline assets such as povetacicept, suzetrigine, and inaxaplin would further erode market share and pricing power, weighing on estimates.

Vertex Pharmaceuticals (VRTX) has been analyzed by 24 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 50% recommend Buy, 8% suggest Holding, 4% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vertex Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Vertex Pharmaceuticals (VRTX) Analyst Forecast & Price Prediction

Get the latest Vertex Pharmaceuticals (VRTX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Vertex Pharmaceuticals (VRTX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vertex Pharmaceuticals (VRTX) Forecast

Analysts have given Vertex Pharmaceuticals (VRTX) a Buy based on their latest research and market trends.

According to 24 analysts, Vertex Pharmaceuticals (VRTX) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $583.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $583.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vertex Pharmaceuticals (VRTX)


Vertex Pharmaceuticals (VRTX) Analyst Forecast & Price Prediction

Get the latest Vertex Pharmaceuticals (VRTX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Vertex Pharmaceuticals (VRTX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover VRTX stock data and trends